Efficacy of empirical therapy with non-carbapenems for urinary tract infections with extended-spectrum beta-lactamase-producing Enterobacteriaceae

International Journal of Infectious Diseases

Volumn 29, Issue , 2014, Pages e91-e95

  Asakura, Takanori ^a,b   Ikeda, Masayuki ^c   Nakamura, Akira ^a   Kodera, Satoshi ^a  

^a ASAHI GENERAL HOSPITAL   (Japan)

^b KEIO UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^c KAGAWA UNIVERSITY HOSPITAL   (Japan)

Author keywords

Beta lactamases; Carbapenems; Cefmetazole; Cephamycins; Urinary tract infections

Indexed keywords

ADICILLIN; AMIKACIN; AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFEPIME; CEFMETAZOLE; CEFOTAXIME; CEFTAZIDIME; CORTICOSTEROID; COTRIMOXAZOLE; GENTAMICIN; IMIPENEM; IMMUNOSUPPRESSIVE AGENT; LEVOFLOXACIN; MINOCYCLINE; PIPERACILLIN PLUS TAZOBACTAM; BETA LACTAMASE;

AGED; ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ARTICLE; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; ESCHERICHIA COLI; EXTENDED SPECTRUM BETA LACTAMASE PRODUCING ENTEROBACTERIACEAE; FEMALE; HOSPITAL CARE; HUMAN; KLEBSIELLA PNEUMONIAE; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MORTALITY; OUTCOME ASSESSMENT; PROTEUS MIRABILIS; RISK FACTOR; TREATMENT DURATION; URINARY TRACT INFECTION; URINE CULTURE; ADULT; BIOSYNTHESIS; DRUG EFFECTS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; ENZYMOLOGY; MICROBIOLOGY; MIDDLE AGED; RETROSPECTIVE STUDY; URINARY TRACT INFECTIONS; VERY ELDERLY;

ADULT; AGED; AGED, 80 AND OVER; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CARBAPENEMS; ENTEROBACTERIACEAE; ENTEROBACTERIACEAE INFECTIONS; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MALE; MIDDLE AGED; RETROSPECTIVE STUDIES; URINARY TRACT INFECTIONS;

EID: 84909629698     PISSN: 12019712     EISSN: 18783511     Source Type: Journal    
DOI: 10.1016/j.ijid.2014.08.018     Document Type: Article

References (20)

1. Pitout J.D., Laupland K.B. Extended-spectrum beta-lactamase-producing Enterobacteriaceae: an emerging public-health concern. Lancet Infect Dis 2008, 8:159-166.
2. Paterson D.L., Bonomo R.A. Extended-spectrum beta-lactamases: a clinical update. Clin Microbiol Rev 2005, 18:657-686.
3. Calbo E., Romaní V., Xercavins M., Gómez L., Vidal C.G., Quintana S., et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harbouring extended-spectrum beta-lactamases. J Antimicrob Chemother 2006, 57:780-783.
4. Doi A., Shimada T., Harada S., Iwata K., Kamiya T. The efficacy of cefmetazole against pyelonephritis caused by extended-spectrum beta-lactamase-producing Enterobacteriaceae. Int J Infect Dis 2013, 17:e159-e163.
5. Schwaber M.J., Carmeli Y. Carbapenem-resistant Enterobacteriaceae: a potential threat. JAMA 2008, 300:2911-2913.
6. Vital signs: carbapenem-resistant, Enterobacteriaceae. MMWR Morb Mortal Wkly Rep 2013, 62:165-170. Centers for Disease Control and Prevention (CDC).
7. Marchaim D., Chopra T., Bhargava A., Bogan C., Dhar S., Hayakawa K., et al. Recent exposure to antimicrobials and carbapenem-resistant Enterobacteriaceae: the role of antimicrobial stewardship. Infect Control Hosp Epidemiol 2012, 33:817-830.
8. Vazquez J.A., González Patzán L.D., Stricklin D., Duttaroy D.D., Kreidly Z., Lipka J., et al. Efficacy and safety of ceftazidime-avibactam versus imipenem-cilastatin in the treatment of complicated urinary tract infections, including acute pyelonephritis, in hospitalized adults: results of a prospective, investigator-blinded, randomized study. Curr Med Res Opin 2012, 28:1921-1931.
9. Harbarth S., Garbino J., Pugin J., Romand J.A., Lew D., Pittet D. Inappropriate initial antimicrobial therapy and its effect on survival in a clinical trial of immunomodulating therapy for severe sepsis. Am J Med 2003, 115:529-535.
10. Venditti M., Falcone M., Corrao S., Licata G., Serra P. Outcomes of patients hospitalized with community-acquired, health care-associated, and hospital-acquired pneumonia. Ann Intern Med 2009, 150:19-26.
11. Performance standards for antimicrobial susceptibility testing. Twenty-first informational supplement. M100-S21 2011, Clinical and Laboratory Standards Institute, CLSI, Wayne, PA.
12. Charlson M.E., Pompei P., Ales K.L., MacKenzie C.R. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 1987, 40:373-383.
13. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference: definitions for sepsis and organ failure and guidelines for the use of innovative therapies in, sepsis. Crit Care Med 1992, 20:864-874. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference Committee.
14. Lee S.S., Kim Y., Chung D.R. Impact of discordant empirical therapy on outcome of community-acquired bacteremic acute pyelonephritis. J Infect 2011, 62:159-164.
15. Blot S., Vandewoude K., De Bacquer D., Colardyn F. Nosocomial bacteremia caused by antibiotic-resistant Gram-negative bacteria in critically ill patients: clinical outcome and length of hospitalization. Clin Infect Dis 2002, 34:1600-1606.
16. Hyle E.P., Lipworth A.D., Zaoutis T.E., Nachamkin I., Bilker W.B., Lautenbach E. Impact of inadequate initial antimicrobial therapy on mortality in infections due to extended-spectrum beta-lactamase-producing Enterobacteriaceae: variability by site of infection. Arch Intern Med 2005, 165:1375-1380.
17. Peña C., Gudiol C., Calatayud L., Tubau F., Domínguez M.A., Pujol M., et al. Infections due to Escherichia coli producing extended-spectrum beta-lactamase among hospitalised patients: factors influencing mortality. J Hosp Infect 2008, 68:116-122.
18. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., et al. Bloodstream infections caused by antibiotic-resistant Gram-negative bacilli: risk factors for mortality and impact of inappropriate initial antimicrobial therapy on outcome. Antimicrob Agents Chemother 2005, 49:760-766.
19. Stuck A.E., Minder C.E., Frey F.J. Risk of infectious complications in patients taking glucocorticosteroids. Rev Infect Dis 1989, 11:954-963.
20. Kang C.I., Kim S.H., Park W.B., Lee K.D., Kim H.B., Kim E.C., et al. Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 2004, 48:4574-4581.